Pregabalin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Pregabalin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

The pregabalin market is projected toregister a CAGR of nearly 3% over the forecast period.

The COVID-19 pandemic has significantly impacted the studied market. Several studies reported that there is a high risk of an increase in the incidence and prevalence of neuropathic pain after the COVID-19 pandemic which might have a positive impact on the market during the pandemic. For instance, according to a research study published in January 2021 in Pain Reports, there is a chance that certain COVID-19-infected patients experience neuropathic pain within a few weeks or months or that neuropathic pain sufferers could experience worsening neurological complications or worsening of their pain. This might have led to increased adoption of pregabalin in COVID-19 patients, driving market growth during the pandemic. In addition, anxiety and sadness were seen in the first year of the COVID-19 pandemic due to factors such as lockdown, social isolation, loneliness, fear of infection, suffering, and death. As pregabalin is used as a treatment for epilepsy, anxiety disorders, and other related disorders, its use is expected to increase with the increase in the burden of disorders around the world. Thus, the pregabalin market is expected to grow over the forecast period. Furthermore, the market has seen lucrative growth post-pandemic and is anticipated to grow significantly during the forecast period due to the rising prevalence of neuropathic pain and epilepsies.

The high and growing prevalence of epilepsy and related disorders, such as neuropathic pain and anxiety disorders, are expected to be primary growth factors for the pregabalin market as the pregabalin market is used in the management and treatment of these disorders. For instance, according to the February 2022 update of the World Health Organization, epilepsy affects about 50 million people worldwide, with 80% of this population residing in low- and middle-income countries. Further, as per the same source, about 5 million cases of epilepsy are diagnosed yearly. As per estimates, up to 70% of people living with epilepsy could avoid seizures with the right diagnosis and care. Thus, with the increasing awareness about the disease, the demand for effective treatment is expected to increase, fueling market growth.

The rising geriatric population with neuropathic pain is expected to fuel growth in the pregabalin market further as pregabalin is used in neuropathic pain treatment. As the geriatric population increases around the world, the burden of neuropathic pain is further expected to increase over the forecast period. For instance, according to the United Nations Department of Economic and Social Affairs 2022, in 2022, there were 771 million people aged 65 years or over globally and the elderly population is projected to reach 994 million by 2030 and 1.6 billion by 2050. As the elderly population is highly prone to complications such as painful diabetic neuropathy and post-herpetic neuralgia, the rising elderly population is anticipated to propel the market growth.

In addition, the launch of new products in the market is further expected to boost market growth over the forecast period. For instance, in May 2022, Lupin Pharmaceuticals received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), pregabalin capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. Therefore, the launch of generic pregabalin is anticipated to drive market growth due to cost-effectiveness and increased availability.

Hence, due to the above-mentioned factors, the pregabalin market is expected to grow over the forecast period. However, the availability of alternative treatments, adverse effects associated with pregabalin, and stringent regulatory policies are expected to restrain the pregabalin market during the forecast period.

Pregabalin Market Trends

Neuropathic Pain Application Segment is Expected to Occupy Significant Share in the Market During the Forecast Period

Neuropathic pain is a type of pain that is frequently persistent, and it typically results from a chronic, progressive nerve illness. However, it can also be brought on by an injury or an infection. An incident or injury does not frequently bring on the discomfort associated with neuropathic pain. Instead, the body sends pain signals to your brain unprompted. The primary causes of neuropathic pain include neuropathic pain diseases, multiple sclerosis, multiple myeloma, diabetic neuropathy, and others, along with injury or infection.

Pregabalin is used to reduce neuropathic pain by blocking the pain signals; thus, with the rising burden of neuropathic pain and its risk factors, the demand for pregabalin is expected to grow, propelling growth in the segment over the forecast period. For instance, according to a review study published in February 2022 in Cureus, about 3-17% of the general population suffers from neuropathic pain, and neuropathy can contribute to chronic pain and be a component of mixed pain syndromes. Hence, the high burden of patients with neuropathic pain is expected to boost the segment's growth during the forecast period.

Further, the rising burden of risk factors for neuropathic pain, like diabetes, is expected to have a crucial impact on the growth of the neuropathic pain segment. For instance, according to the September 2021 report of the International Diabetes Federation, about 537 million adults aged 20-79 years were living with diabetes in 2021, and the total number of people living with diabetes is projected to rise to 643 million in next seven years and 783 million in next 22 years.

Moreover, as per the article published in UpToDate in December 2022, diabetic polyneuropathy is the most common neuropathy across many regions worldwide. Furthermore, approximately 50 per cent of patients with diabetes will eventually develop neuropathy. Therefore, the rising population of diabetes, along with the rising diabetic population, is anticipated to drive the segment growth.

Therefore, the rising prevalence of diabetes and neuropathic pain will drive the segment growth.

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

North America is expected to have significant market growth over the forecast period.

The factors driving the growth are attributed to the growing prevalence of epilepsy and related diseases, the rising geriatric population, the strong foothold of key market players, and the availability of pregabalin in the region.

The high prevalence of epilepsy in the United States is anticipated to drive the market growth. For instance, according to the National Institute of Neurological Disorders and Stroke data reviewed on April 2023, in the United States, 2.3 million people and more than 450,000 kids and teenagers suffer from epilepsy. An estimated 150,000 people receive an epilepsy diagnosis each year. Such a huge prevalence of epilepsy is anticipated to increase the adoption of pregabalin to reduce abnormal brain activity, driving market growth in the region.

Similarly, according to the September 2021, report of Statistics Canada, approximately one in four (25%) Canadians aged 18 and older screened positive for symptoms of depression, anxiety, or posttraumatic stress disorder (PTSD) in spring 2021, up from one in five (21%) in fall 2020. Hence, the demand for pregabalin is expected to increase in the region, and the market is anticipated to grow over the forecast period.

Further, the new product approvals in the country and their launch are expected to boost pregabalin market growth over the forecast period. The United States Food and Drug Administration (USFDA) approved Zydus' Pregabalin Capsules of strength 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. The approval of drugs in the United States is anticipated to contribute to the market growth in the region.

Therefore, due to factors such as the rising prevalence of neurological disorders and key initiatives adopted by market players, the North American region is expected to occupy a significant share of the pregabalin market over the forecast period.

Pregabalin Industry Overview

The pregabalin market is moderately competitive with a number of established market players. The factors owing to the competition include approvals of generic drugs, rising partnerships among key market payers, and rising launch of different pregabalin formulations, among others. Some of the players operating in the market include Viatris Inc, Amneal Pharmaceuticals LLC, Zydus Group, Sciegen Pharmaceuticals Inc., Teva Pharmaceuticals, Rising Pharmaceuticals Inc., MSN Laboratories Ltd, and Cipla Limited.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support